Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.

Toby M Maher,Susanne Stowasser,Florian Voss,Elisabeth Bendstrup,Michael Kreuter,Fernando J Martinez,Patricia J Sime,Christian Stock

Respirology (Carlton, Vic.)（2023）

引用 0|浏览7

暂无评分

摘要

Data from clinical trials in subjects with pulmonary fibrosis of diverse aetiology demonstrate a strong association between decline in FVC % predicted and mortality over 52 weeks, supporting FVC decline as a surrogate for mortality in these patients.

查看译文

关键词

clinical trial, interstitial lung disease, pulmonary function tests, vital capacity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要